Bevasiranib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bevasiranib
Accession Number
DB06642
Type
Biotech
Groups
Investigational
Biologic Classification
Gene Therapies
Other gene therapies
Description

Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).

Synonyms
  • Bevasiranib
Product Ingredients
IngredientUNIICASInChI Key
Bevasiranib sodiumII3PQ3910V849758-52-7Not applicable
Categories
UNII
DGN36694W4
CAS number
959961-96-7

Pharmacology

Indication

Investigated for use/treatment in macular degeneration and diabetic retinopathy.

Pharmacodynamics

Bevasiranib represents the first drug in a promising new class of experimental medical treatments. It is a small interfering RNA (siRNA) drug, which silences the genes that produce Vascular Endothelial Growth Factor (VEGF), a protein that promotes blood vessel growth. The treatment slows the growth and leakage of abnormal blood vessels that are associated with the wet form of macular degeneration. The drug is injected directly into the eye.

Mechanism of action
TargetActionsOrganism
UVascular endothelial growth factor ANot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMacular Degeneration1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentMacular Degeneration1
3TerminatedTreatmentMacular Degeneration1
3WithdrawnTreatmentAge Related Macular Degeneration (ARMD) / Age-Related Macular Degeneration (ARMD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Vascular endothelial growth factor receptor binding
Specific Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
Gene Name
VEGFA
Uniprot ID
P15692
Uniprot Name
Vascular endothelial growth factor A
Molecular Weight
27042.205 Da
References
  1. Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ: Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis. 2008 May 28;14:997-1005. [PubMed:18523657]

Drug created on March 19, 2008 10:43 / Updated on March 01, 2020 23:45

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates